Chagas disease, caused by the parasite Trypanosoma cruzi, is transmitted to people by insect vectors (triatomines) and is found only in the Americas (mainly, in rural areas of Latin America). If untreated, infection persists for decades and can be life-threatening. It is estimated that as many as 8 million people in Mexico, Central America, and South America have Chagas disease, and an estimated 300,000 infected people are living in the United States. Although there are triatomine bugs in the United States, relatively few autochthonous cases of Chagas disease have been reported. Because of blood donor screening and increasing awareness among the general public and healthcare providers, more people are being diagnosed and seeking care, and current efforts to raise awareness of this parasitic infection may increase the numbers of people being diagnosed with Chagas disease. This panel will address the value of public health in the management of these patients, including the impact of adding Chagas disease to the list of reportable conditions in one southern state, outreach to and activities in immigrant communities most at risk of chronic infections, investigating potential congenital transmission, infection transmission or reactivation in transplant recipients, and the identification of T. cruzi positive triatomine bugs in the United States leading to concerns regarding autochthonous transmission.